Drug updated on 9/4/2024
Dosage Form | Capsule (oral; 100 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Latest News
Summary
- Inrebic (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Spleen Volume Reduction and Total Symptom Score Reduction in Myelofibrosis: Fedratinib and ruxolitinib were confirmed as effective for spleen volume reduction and symptom score reduction in a systematic review and network meta-analysis of 1953 patients. Momelotinib showed comparable efficacy to ruxolitinib, with reduced toxicity in erythrocytes and platelets.
- Mortality and Clinical Improvement in COVID-19: The meta-analysis of 1190 hospitalized COVID-19 patients indicated that JAK inhibitors, including fedratinib, were associated with a reduced risk of mortality (OR 0.51) and improved clinical outcomes (OR 1.76).
- Fedratinib and ruxolitinib exhibited distinct tolerance profiles, with Momelotinib showing a favorable effect on anemia. Pacritinib demonstrated higher toxicity concerning erythrocytes and platelets compared to Momelotinib in myelofibrosis patients.
- The safety outcomes were not explicitly discussed in the study on COVID-19 treatment, and no comparative safety analysis among the JAK inhibitors was provided.
- There is no population or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Inrebic (fedratinib) Prescribing Information. | 2023 | Bristol-Myers Squibb, New York, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. | 2021 | Blood Cancer Journal |
The use of Janus kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. | 2021 | Clinical Epidemiology and Global Health |